942070-47-5

Basic information

• Product Name: 1-Boc-7-Azaindole-3-boronic acid pinacol ester
• Synonyms: 1-Boc-7-Azaindole-3-boronic acid pinacol ester;1-Boc-7-Azaindole-3-boron...;tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate;tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylat;N-Boc-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-azaindole;tert-butyl 3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate;tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine-1-carboxylate;tert-Butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxy
• CAS NO: 942070-47-5
• Molecular Formula: C₁₈H₂₅BN₂O₄
• Molecular Weight: 344.216
• EINECS: 1308068-626-2
• Product Categories: Azaindoles
• Mol File: 942070-47-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 115-117 °C
• Boiling Point: 460.9±48.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 2.68±0.30(Predicted)
• CAS DataBase Reference: 1-Boc-7-Azaindole-3-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-7-Azaindole-3-boronic acid pinacol ester(942070-47-5)
• EPA Substance Registry System: 1-Boc-7-Azaindole-3-boronic acid pinacol ester(942070-47-5)

Safety Data

• Hazardous Substances Data: 942070-47-5(Hazardous Substances Data)

Usage

General Description

1-Boc-7-Azaindole-3-boronic acid pinacol ester is a chemical compound containing a boronic acid functional group, commonly used in organic synthesis. It is a derivative of 7-Azaindole, a nitrogen-containing heterocycle, with a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom. The pinacol ester group provides steric hindrance and stability to the boronic acid functionality, making it a valuable reagent in Suzuki-Miyaura cross-coupling reactions and other organic transformations. 1-Boc-7-Azaindole-3-boronic acid pinacol ester is utilized in the preparation of pharmaceuticals, agrochemicals, and other fine chemicals, making it an important intermediate in the synthesis of various biologically active compounds.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 192189-18-7 tert-butyl 3-iodo-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 226085-17-2 tert-butyl 3-bromo-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 138343-77-8 1-(tert-butoxycarbonyl)-1H-pyrrolo<2,3-b>pyridine 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 271-63-6 7-Azaindole 
• 23616-57-1 3-iodo-1H-pyrrolo[2,3-b]pyridine 
• 74420-15-8 3-bromo-1H-pyrrolo[2,3-b]pyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1309365-29-4 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)phenol 
• 1309365-27-2 2-(1H-pyrrolo[2,3-b]pyridin-3-yl)benzenamine 
• 341998-55-8 Meriolin 1 
• 1316228-69-9 3-(1-benzyl-1H-pyrazole-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 945256-29-1 3‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)‐1H‐pyrrolo[2,3‐b]pyridine 
• 1416000-85-5 tert-butyl 3-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate 

Relevant articles and documents

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clinical trials of CDK4/6 inhibitors for MM. To discover novel CDK6 inhibitors with better potency and high druggability, structure-based virtual screening was conducted to identify compound 10. Further chemical optimization afforded a better derivative, compound 32, which exhibited strong inhibition of CDK4/6 and showed high selectivity over 360+ kinases, including homologous CDKs. The in vivo evaluation demonstrated that compound 32 possessed low toxicity (LD50 > 10,000 mg/kg), favorable bioavailability (F% = 51%), high metabolic stability (t1/2 > 24 h) and strong anti-MM potency. In summary, we discovered a novel CDK4/6 inhibitor bearing favorable drug-like properties and offered a great candidate for MM preclinical studies.

Five-membered heterocyclic oxo carboxylic acid compound and medical application thereof

The invention relates to a five-membered heterocyclic oxo carboxylic acid compound and a medical application thereof. Specifically, the invention relates to a compound, a pharmaceutical salt, a prodrug, a hydrate, a solvate or a crystal form as shown in a formula (I), and also relates to a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the pharmaceutical composition as a secretion regulator of interferon type I, especially as an STING agonist in preparation of medicines for preventing and/or treating I-type interferon related diseases.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.